Clinical development and economic prospects of CAR T cell immunotherapies

Bookmark and Share
Published: 25 Apr 2018
Views: 3635
Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA

Dr Velamehr speaks with ecancer at AACR 2018 about developing a cell bank for quicker production of CAR-T cell therapy.

Dr Velamehr outlines the utility of clinical experience working with induced pluripotent stem cells (IPSCs), the broader economic viability of CAR T cell therapy, and scaling production to improve the availability and viability of off-the-shelf approaches to immunotherapy.

Watch his presentation at the conference here.